Dr. Reddys Labs (RDY) Reports Q2 EPS of $0.27

Dr. Reddys Labs (NYSE: RDY) reported Q2 EPS of $0.27, versus $0.63 reported last year. Revenue for the quarter came in at $539 billion, versus $599 billion reported last year.

Commenting on the results, Co-chairman and CEO, G V Prasad said, “All our major businesses have shown sequential improvement over the previous quarter with revenues growing by 11% and EBITDA by 61%. We have made considerable progress in our remediation efforts and continue to work on addressing the concerns of the regulators. Looking ahead we will continue to focus on launching new products in our generics business, improving productivity and strengthening our quality management systems.”

For earnings history and earnings-related data on Dr. Reddys Labs (RDY) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Nomura Holdings (NMR) Reports In-Line Q1 EPS
• Customers Bancorp (CUBI) Tops Q1 EPS by 3c